Amgen, Actelion Talk but No Offer Made
THOUSAND OAKS, California (
) --
Amgen's
(AMGN) - Get Report
CEO Kevin Sharer met with his counterpart at
Actelion
to discuss Amgen's interest in the Swiss biotechnology company but no formal offer was made,
Bloomberg
reports.
Sharer met with Actelion CEO Jean-Paul Clozel last week,
Bloomberg
reports, citing three people with knowledge of the situation.
Sharer told Clozel that Amgen was studying the situation, one of the people said. Clozel wants to keep the company independent yet stay on good terms with a potential suitor, another of the people said, according to
Bloomberg
.
Actelion has a market value of 6.8 billion Swiss francs ($6.9 billion).
Bloomberg
first reported in mid-November
.
Analysts speculate Amgen could pay $9.8 billion, or $75 a share, for Actelion,
Reuters
reports.
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
Joseph Woelfel
>To submit a news tip, send an email to:
.